Spironolactone Tablet, Film Coated
Product Images NDC 43063-832

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Spironolactone (NDC 43063-832). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

43063832 Label (43063832)

The text is a description of a medication called Spironolactone, which comes in film-coated 25 mg tablets. There are three bottles of 30 tablets each, all with the same lot number and expiration date. Patients should take the tablet(s) as directed by their doctor and may experience side effects, which they can report to the FDA. The tablets are yellow, round, and marked with the identifier of the pharmaceutical company that manufactured them. There are also barcodes with product information. The rest of the text appears to be errors generated by and is not useful.*

FDA Label Image

Figure 1. Survival By Treatment Group In The Randomized Spironolactone Evaluation Study (Spironolactone Figure 1)

This appears to be a partial output of a statistical analysis report showing a p-value result for a log-rank test. It also includes a time frame in months ranging from 12 to 48. However, without more context or complete information, it is difficult to provide a meaningful description.*

FDA Label Image

Figure 2. Hazard Ratios Of All-cause Mortality By Subgroup In The Randomized Spironolactone Evaluation Study (Spironolactone Figure 2)

This is a chart or table showing the results of a subgroup analysis comparing the efficacy of spironolactone versus placebo. The data is presented in a horizontal bar graph format with values on the y-axis ranging from 0 to 5. The x-axis shows different time points, from 02 to 1.4. The results indicate which treatment (spironolactone or placebo) was found to be "better" for the specific subgroup being analyzed.*

FDA Label Image

Chemical Structure (Spironolactone Structure Image)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.